HSPA13

Across TCGA pan-cancer cohorts, HSPA13 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated HSPA13 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher HSPA13 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HSPA13 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

BRCA, ACC, and KIRC are the cancer types where HSPA13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.676	0.963	<.001	32	view →
ACC	OS	Median	All	0.114	0.892	<.001	24	view →
KIRC	OS	Median	All	0.266	0.805	.017	12	view →
LGG	OS	Median	All	0.142	0.909	<.001	12	view →
BLCA	DFS	Median	All	1.000	0.327	.026	10	view →
SARC	OS	Median	All	0.156	0.767	.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	0.959	0.625	.021	4	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

HSPA13–BRCA (OS)

Open the BRCA breakdown →